Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02293018 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of MTC896 Gel in Subjects With Acne
A Phase 1 study, sponsored by Mimetica Pty Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02293018: Completed Phase 1 study, sponsored by Mimetica Pty Limited.
NCT02293018 is a Phase 1 study that has completed, run by Mimetica Pty Limited. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02293018, a Phase 1 study, has completed, sponsored by Mimetica Pty Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the pharmacokinetic properties of topically applied MTC896 Gel following application of 0.75% (w/w) MTC896 Gel once daily and twice daily and 1.5% (w/w) once daily over 4 weeks in the treatment of acne.
Primary Outcome
The primary pharmacokinetic outcome measure will be the maximum concentration (Cmax) of MTC896 in the plasma after 28 days of treatment.
Interventions
- DRUG 0.75% (w/w) MTC896 Gel Once Daily
- DRUG 0.75% (w/w) MTC896 Gel Twice Daily
- DRUG 1.5% (w/w) MTC896 Gel Once Daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
What the finished NCT02293018 record still lists
NCT02293018 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 3 interventions - of which 0.75% (w/w) MTC896 Gel Once Daily is the first listed.
NCT02293018 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02293018 about?
NCT02293018 is a clinical study titled "Pharmacokinetic Study of MTC896 Gel in Subjects With Acne". The purpose of this study is to determine the pharmacokinetic properties of topically applied MTC896 Gel following application of 0.75% (w/w) MTC896 Gel once daily and twice daily and 1.5% (w/w) once daily over 4 weeks in the treatment of acne.
What is the current status of trial NCT02293018?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2014-08. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02293018?
The interventions under investigation include: 0.75% (w/w) MTC896 Gel Once Daily (DRUG), 0.75% (w/w) MTC896 Gel Twice Daily (DRUG), 1.5% (w/w) MTC896 Gel Once Daily (DRUG).
Who is sponsoring clinical trial NCT02293018?
This trial is sponsored by Mimetica Pty Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02293018's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia